Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.

NCT04652206 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Adenocarcinoma
Inoperable Disease
Localized Pancreatic Adenocarcinoma

Interventions

DRUG: SCO-101
DRUG: Gemcitabine
DRUG: Nab paclitaxel

Sponsor

Scandion Oncology A/S

Collaborators

[object Object]